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a  b  s  t r  a  c  t
Hyaluronan  (HA) is  frequently  incorporated  in eye  drops  to extend  the  pre-corneal  residence  time,  due  to
its  viscosifying  and  mucoadhesive  properties.  Hydrodynamic  and  rheological  evaluations  of  commercial
products  are  ﬁrst  accomplished  revealing  molecular  weights  varying  from  about  360 to about  1200  kDa
and  viscosity  values  in the  range  3.7–24.2  mPa  s. The  latter  suggest  that  most  products  could  be optimized
towards  resistance  to drainage  from  the  ocular  surface.  Then,  a study  aiming  to maximize  the  viscosity
and  mucoadhesiveness  of  HA-based  preparations  is  performed.  The  effect  of polymer  chain  length  and
concentration  is investigated.  For  the  whole  range  of  molecular  weights  encountered  in  commercial  prod-
ucts, the  concentration  maximizing  performance  is identiﬁed.  Such  concentration  varies  from  0.3  (wt%)
for a 1100  kDa  HA  up to 1.0  (wt%)  for a 250 kDa  HA,  which  is 3-fold  higher  than  the highest  concentrationucoadhesiveness
orneal epithelial cells
on  the market.  The  viscosity  and  mucoadhesion  proﬁles  of optimized  formulations  are  superior  than
commercial  products,  especially  under  conditions  simulating  in vivo  blinking.  Thus  longer  retention  on
the  corneal  epithelium  can be  predicted.  An  enhanced  capacity  to protect  corneal  porcine  epithelial  cells
from  dehydration  is  also  demonstrated  in vitro.  Overall,  the  results  predict  formulations  with  improved
efﬁcacy.
© 2016  The  Author(s).  Published  by  Elsevier  Ltd.  This  is  an open  access  article  under  the  CC  BY-NC-ND. Introduction
Topical applications currently represent the main route of
dministration of drugs used to treat many eye disorders, includ-
ng dry eye, conjunctivitis, post-operative inﬂammation, etc. and
ye drops are the formulation of choice for the delivery (Almeida,
maral, Lobão, & Lobo, 2013; Davies, 2000; Di Colo, Zambito, Zaino,
 Sansò, 2009; Van Santvliet & Ludwig, 2004). One of the main chal-
enges associated with the use of conventional topical ophthalmic
ormulations is the short retention time of the components on the
cular surface. After instillation, there is drainage of the exogenous
ubstances, mainly due to blinking and lachrymation that lowers
he efﬁcacy. Frequent instillations would be necessary to maintain
he drug concentration in the tear ﬁlm at a pharmacological level;
lthough, this would worsen patient compliance and lead to ocular
nd systemic side effects (Almeida et al., 2013; Davies, 2000 Davies,
arr, Hadgraft, & Kellaway, 1991; Di Colo et al., 2009; Ludwig, 2005;
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McKenzie & Kay, 2015; Séchoy et al., 2000; Snibson et al., 1990;
Van Santvliet & Ludwig, 2004). Introduction of mucoadhesive poly-
mers is one of the most used strategies to prolong the contact
time of the preparation with the corneal/conjunctival epithelium
(Davies et al., 1991; Davies, 2000; Di Colo et al., 2009; Ludwig,
2005; Séchoy et al., 2000; Snibson et al., 1990). The incorporation
of macromolecules increases the formulation viscosity; therefore,
the drainage rate from the pre-corneal area is reduced. Moreover,
mucoadhesive macromolecules are able to intimately interact with
the mucin layer, covering the corneal and conjunctival surfaces of
the eye. This adhesive capacity further prolongs precorneal reten-
tion, improving the ocular bioavailability of the active agent (Davies
et al., 1991; Davies, 2000; Di Colo et al., 2009; Ludwig, 2005; Séchoy
et al., 2000; Snibson et al., 1990).
Both the mucoadhesiveness and viscosity of the preparations
are mainly dependent on polymer molecular weight and concen-
tration; therefore, these parameters have to be adjusted for optimal
performance (Di Colo et al., 2009). When tuning the formula-
tion, limits concerning viscosity must be considered. It has been
reported that ﬁnal viscosity should not exceed 30 mPas; other-
wise, discomfort due to blurred vision and foreign body sensation
occurs, resulting in a faster elimination due to reﬂex tears and
blinks (Oechsner & Keipert, 1999; Pires et al., 2013). Thus, an ideal
e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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reparation should have the maximal contrast to drainage without
xcessively increasing viscosity.
Hyaluronic acid sodium salt (hyaluronan, HA) is commonly
sed as a bioavailability-enhancer in eye drops (Ludwig, 2005;
iao, Jones, Forbes, Martin, & Brown, 2005; Tong, Petznik, Yee,
 Tan, 2012; Zambito & Di Colo, 2011). In the presence of HA,
he precorneal residence times of pilocarpine, timolol, aceclidine,
ropicamide, arecoline, gentamicin, and tobramycin were pro-
onged (Bernatchez, Tabatabay, & Gurny, 1993; Liao et al., 2005).
n addition to its viscosifying and mucoadhesive properties, HA
as other beneﬁcial effects on the corneal epithelium, including:
) protection against dehydration, 2) reduction of healing time, 3)
eduction of the inﬂammatory response caused by dehydration, and
) lubrication of the ocular surface (Aragona, Di Stefano, Ferreri,
pinella, & Stilo, 2002; Di Colo et al., 2009; Guillaumie et al., 2010;
udwig, 2005; Tong et al., 2012; Zambito & Di Colo, 2011; Zheng,
oto, Shiraishi, & Ohashi, 2013;). Due to this clinical efﬁcacy, HA
s largely used in ophthalmology not only as an excipient but also
s the main component of the artiﬁcial tear substitutes commonly
rescribed for the treatment of dry eye disease (Aragona et al.,
002; Johnson, Murphy, & Boulton, 2006; Ludwig, 2005; McDonald,
aye, Figueiredo, Macintosh, & Lockett, 2002; Snibson et al., 1990;
heng et al., 2013). High-performing HA-based eye drop formula-
ions are of great clinical interest.
There are limited scientiﬁc data on HA-containing products for
opical ophthalmic use. These include the HA concentration range
enerally used (0.1–0.4 wt%; the HA concentration is also indicated
n the package inserts of the commercialized products) and the
iopolymer weight average molecular weight (Mw), which varied
rom 155 to 1400 kDa in 11 commercial products (Guillaumie et al.,
010; Johnson et al., 2006; Liu, Harmon, Maziarz, Rah, & Merchea,
014; McDonald et al., 2002). No viscosity or mucoadhesiveness
ata are reported. To address this, we performed hydrodynamic
nd rheological characterizations on six additional products in this
tudy and found most available formulations do not exhibit optimal
iscosity. Therefore, we aimed to determine novel, optimized for-
ulations by varying the HA Mw and concentrations (considering
he range of molecular weights commercially used) to maximize
he mucoadhesiveness and viscosity while maintaining the latter
ithin suitable limits. Such formulations are expected to exhibit
he maximum practical retention on the corneal epithelium in vivo.
e determined the viscosity and mucoadhesion proﬁles of selected
reparations and their capacity to protect the corneal epithelium
gainst dehydration in vitro using porcine corneal epithelial cells.
he preparations were also compared with commercial products.
. Materials and methods
.1. Materials
Hyaluronic acid sodium salt, lot. N. 02622 (HA1100) and
yaluronic acid sodium salt, lot. N. 11004 (HA250) were kindly pro-
ided by Altergon srl (Italy). Hyaluronic acid sodium salt (HA800
nd HA500) were produced as described below. Six commercial HA-
ased formulations indicated for the treatment of dry eye syndrome
ere evaluated in this work: Bluyal (SOOFT italia S.p.A., Fermo,
taly, multi-dose bottle, 8 mL,  HA 0.15%), Blugel (SOOFT italia S.p.A.
ermo, Italy, multi-dose bottle, 8 mL,  HA 0.30%), Hyabak (Laborato-
ios Thea, Barcelona, Spain, multi-dose bottle, 10 mL;  HA 0.15%,)
rtelac Splash MDSC (Fabrik GmbH, Berlin, Germany multi-dose
ottle, 10 mL  HA 0,24%,) Hyalistil Bio (S.I.F.I S.p.A., Catania, Italy,
ulti-dose bottle, 10 mL,  0,2%), and Octilia Natural (C.O.C. Farma-
eutici S.r.l., Bologna, Italy, 10 single-dose vials x 0.5 mL). Mucin
from porcine stomach type II, cat. N. M2378), Na3PO4 (cat. N.
42483), NaH2PO4·2H2O, cat. N. 71505, Na2HPO4·2H2O (cat. N.ymers 153 (2016) 275–283
71643), EDTA (ethylenediaminetetraacetic acid disodium salt dihy-
drate, cat. N. E5134), and sodium hydroxymethylglycinate (Cat. N.
CDS003712) were all purchased from Sigma-Aldrich (Milan, Italy).
Dulbecco’s Phosphate Buffered Saline (PBS) without calcium and
magnesium was  purchased from Lonza Sales Ltd, (Switzerland, cat.
N. BE17-516F).
2.2. HA800 and HA500 preparation
HA800 and HA500 samples were prepared by hydrolysing a HA
powder (lot. N. 08748 Mw = 1584 ± 100 kDa; Mw/Mn = 1.70) under
heterogeneous acid conditions, as reported elsewhere with slight
modiﬁcations (D’Agostino et al., unpublished). In brief, a certain
amount of the HA powder was  dispersed in ethanol (93% v/v)
(ethanol/HA 10 mL/g). The dispersion was pre-warmed at 65 ◦C
and HCl (37 wt%) was added under vigorous stirring, resulting in
a 0.2 M HCl ﬁnal concentration. The hydrolysis was carried out for
50 min  to obtain HA800 and for 110 min  to obtain HA500. Reactions
were stopped by adding Na3PO4 (0.35 M)  until neutralized, while
cooling in an ice/water bath. Products were puriﬁed by washing
in ethanol/water (8/2 v/v) to remove phosphate salts. Puriﬁcation
was monitored using conductivity measurements: a conductivity
in the range of 30–40 S/cm was  the target value. Samples were
then treated with pure ethanol and dried under vacuum at 40 ◦C.
The resulting sodium hyaluronate powders will be referred to as
HA800 and HA500.
2.3. Hydrodynamic characterization of HA using a SEC-TDA
system (Viscotek)
The HA samples and commercial products were characterized
using SEC-TDA (Size Exclusion Chromatography-Triple Detector
Array) equipment by Viscotek (Lab Service Analytica, Italy). A
detailed description of the system and its analytical conditions
were reported elsewhere (La Gatta, Schiraldi, Papa, & De Rosa,
2011; La Gatta, De Rosa, Marzaioli, Busico, & Schiraldi, 2010).
The molecular weight (Mw, Mn, Mw/Mn), molecular size (hydro-
dynamic radius-Rh), and intrinsic viscosity ([]) distributions of
samples were derived. Each sample was analyzed in triplicate;
results were reported as means ± SD. The Mark-Houwink-Sakurada
(MHS) curves (log [] vs log Mw) were also directly obtained (La
Gatta et al., 2010, 2011).
2.4. Rheological evaluation
Rheological measurements were carried out using a Physica
MCR301 oscillatory rheometer (Anton Paar, Germany) equipped
with a coaxial cylinders geometry (CC27-SN7969; measuring cup
diameter/measuring bob diameter: 1.0847 according to ISO 3219;
gap length 39.984 mm;  sample volume 19.00 mL) and a Peltier tem-
perature control.
2.4.1. Viscosity measurements
The HA1100, HA800, HA500, and HA250 powders were dis-
solved at different concentrations (in the range 0.15–1.5 wt%) in
NaH2PO4·2H2O (2.2 g/L), Na2HPO4·2H2O (9.5 g/L), sodium hydrox-
ymethylglycinate (0.04 g/L), EDTA (1.1055 g/L), and NaCl (4.3 g/L) in
H2O. This was  the composition of the buffer (pH 7.4) in commercial
products. The dynamic viscosity of the samples was registered as
a function of shear rate (1–1000 s−1) at 35 ◦C, using 50 measuring
points and no time setting. From each ﬂow curve, the value of zero-
shear viscosity (0, viscosity in the range of Newtonian plateau)
was obtained. Each solution was  prepared in triplicate and each
resulting sample was  analyzed once, therefore, three ﬂow curves
were registered for each HA solution. The 0 values reported were
the mean values of the three measurements. For all solutions tested,
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alues of each measurement presented a maximal standard devia-
ion from the mean value lower than 3%. For each HA sample, the
ependence of 0 (mean value) on concentration was derived.
Flow curves for commercial products were collected under the
ame conditions. For each determination, samples were taken from
iverse bottles/vials of the same batch in order to reach the volume
eeded for the measurement (19 mL). Three ﬂow curves of different
amples from the same batch were registered for each product and
he zero-shear viscosity values reported are the mean. For each
ormulation, the maximal standard deviation registered was less
han 5%.
.4.2. Mucoadhesion measurements
The mucoadhesiveness of the HA solutions was evaluated by
eans of viscosity measurements as previously described with
odiﬁcations (Hassan & Gallo, 1990; Oechsner & Keipert, 1999;
ccello-Barretta et al., 2010). In particular, the following samples
ere prepared for each determination:
) a suspension of mucin (10 wt%) in the buffer indicated in section
2.4.1;
) a HA solution in the same buffer at a certain concentration; and
) a suspension containing mucin (10 wt%) and the polymer under
investigation at the same concentration as in the sample 2. A
ﬂow curve in the range of 1–1000 s−1 was registered at 35 ◦C
for each sample (50 measuring points, no time setting). At each
value of shear rate, the mucoadhesiveness of sample 2 was
expressed as:
(%) = [muc+HA − (muc + HA)]/(muc + HA) × 100
here (%) is the mucoadhesion index, muc is the dynamic vis-
osity of sample 1, HA is the dynamic viscosity of sample 2, and
muc+HA is the dynamic viscosity of sample 3.
For a mucoadhesive polymer, muc+HA is higher than
muc + HA) due to the interaction occurring between the polymer
nd mucin, and (%) is a measure of the mucoadhesion strength
Hassan & Gallo, 1990; Oechsner & Keipert, 1999; Uccello-Barretta
t al., 2010).
Samples 1, 2, and 3 were prepared as follows. Sample 1): mucin
as hydrated with sterile water to 15 wt% ﬁnal concentration (10 h,
00 rpm, room temperature). The pH of the resulting suspension
as 3.8–4.0. Then, Na3PO4 (0.35 M)  was added to bring the pH to
.0–7.6. Water was added to a 10 wt% ﬁnal mucin concentration.
ample 2): HA was dissolved at the desired (wt%) concentration in
 phosphate buffer with the same pH and salt concentration as sam-
le 1. Sample 3): a mucin suspension, 15 wt%, was  buffered using
a3PO4 (0.35 M).  Then a small volume of a highly concentrated HA
olution in pure water was added to a ﬁnal HA concentration equal
o that of sample 2. Water was added to the ﬁnal volume. The ﬁnal
H and conductivity values were in the range 7.0–7.6 and 12.0–14.0
S/cm, respectively, for all samples. The pH and conductivity vari-
tions within these ranges did not affect viscosity.
For each HA solution, the protocol described above was per-
ormed in triplicate and the mucoadhesion index was  reported as
he mean value. The maximal standard deviation registered was
ess than 5%.
.4.3. Oscillatory measurements
Oscillatory measurements were performed to ascertain the
ature of the interaction of the formulations with mucin
Ceulemans & Ludwig, 2002). Dispersions containing mucin and the
A sample, at the selected concentration, prepared as described in
he paragraph 2.4.2 (sample 3), were measured. The dynamic mod-
li of the mixtures were evaluated as functions of the oscillationymers 153 (2016) 275–283 277
stress and frequency. In particular, strain sweep tests were per-
formed at a constant oscillatory frequency of 0.1 s−1 over a strain
amplitude range of 0.01–100%, with no time setting at 35 ◦C. Oscil-
lation frequency sweep tests were then carried out over a frequency
range of 0.1–10 s−1 at a constant strain selected within the linear
viscoelastic range (0.045%), with no time setting at 35 ◦C.
Three different samples were analyzed for each dispersion; the
resulting curves overlapped.
2.5. In vitro evaluation of corneal (epithelial cells) protection
against dehydration
2.5.1. Cell culture and growth conditions
Primary porcine corneal epithelial cells (PCECs) were a gift from
A.O.R.N. Antonio Cardarelli, Centre of Biotechnologies (Naples).
Cells were cultured in Dulbecco’s Modiﬁed Eagle’s Medium
(DMEM) containing 15% (w/v) foetal bovine serum (FBS), 10 ng/ml
human epidermal growth factor (EGF), and 40 g/ml gentamicin,
in a humidiﬁed atmosphere of 5%CO2–95%air at 37 ◦C (Zheng et al.,
2013). All materials were purchased from Invitrogen (Milan, Italy)
except for gentamicin, which was purchased from Fisiopharma S.r.l.
(Salerno, Italy).
2.5.2. Evaluation of cell viability after dehydration
The protective effect of the selected formulas against dehy-
dration was evaluated using previously reported protocols, with
modiﬁcations (Hill-Bator, Misiuk-Hojlo, Marycz, & Grzesiak, 2014;
Matsuo, 2001; Rangarajan, Kraybill, Ogundele, & Ketelson, 2015;
Zheng et al., 2013). Speciﬁcally, cells were seeded in 24-multiwell
plates (5 × 104/well) and in DMEM containing 15% FBS until
70% conﬂuence was reached. The medium was then replaced
with selected HA formulations (HA1100-0.28%, HA500-0.67%, and
HA250-1.03% (wt% solutions prepared in cell culture medium) and
with the same solutions diluted 1:3, 1:10, and 1:30. For the pos-
itive and negative controls, the medium was replaced with fresh
medium not containing HA. Cells were incubated under cell cul-
ture conditions for 2 h. Cells treated with the HA  samples and not
treated (negative control, NC) were then dehydrated: the medium
was removed and the multiwells were incubated at 37 ◦C without
the lid until a stress response (morphological change) was evident
in the NC (about 20 min). The positive control (CTR, not treated
with HA), was not dehydrated (cells were kept in the presence of
the medium during all experiments). Cell viability was then evalu-
ated using the Presto Blue assay (Cat. N. A13261, Invitrogen, GIBCO)
according to manufacturer’s instructions. When added to cells, the
cell-permeable PrestoBlue reagent, resazurin, is modiﬁed into reso-
furin by the reducing environment of viable cells. The conversion is
proportional to metabolically active cells and was quantitatively
determined by absorbance measurements. Cell viability (%) was
calculated with respect to the positive control (100% viability).
Each sample was tested in triplicate. Results were reported as
means ± SD. A Student t-test was  used for statistical analysis and p
values <0.05 were considered statistically signiﬁcant differences.
3. Results and discussion
3.1. Hydrodynamic and rheological characterization of
commercial formulations
In this study, we ﬁrst evaluated commercially available HA-
based eye-drops. The results of the hydrodynamic and rheological
characterizations are reported in Table 1 and in Fig. 1. In partic-
ular, the sample molecular weight (Mw, Mn, Mw/Mn), molecular
size (hydrodynamic radius-Rh), intrinsic viscosity ([]), and the
biopolymer concentration derived from SEC-TDA analyses, are
shown in Table 1. The molecular weight of HA varied from ∼ 360
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Table 1
Hydrodynamic and rheological data for the commercial formulations. The values of weight average molar mass (Mw), numeric average molar mass (Mn), polydispersity index
(Mw/Mn), intrinsic viscosity ([]), hydrodynamic radius (Rh), and HA concentration (wt%) derived from the SEC-TDA analyses are reported. The values of zero-shear viscosity
(0) derived from the ﬂow curves (Fig. 1b) are also reported.
Sample SEC-TDA analysis Rheological analysis
HA (wt%) Mw (kDa) Mn(kDa) Mw/Mn [] (dL/g) Rh(nm) 0 (mPa s)
Bluyal 0.14 ± 0.01 1130 ± 30 690 ± 60 1.6 ± 0.1 18.6 ± 0.7 67 ± 2 6.7
Blugel 0.29 ± 0.01 1070 ± 10 640 ± 40 1.6 ± 0.1 17.7 ± 0.2 64 ± 1 24.2
Hyaback 0.15 ± 0.01 360 ± 20 230 ± 50 1.6 ± 0.2 8.8 ± 0.5 35 ± 3 2.3
Artelac Splash 0.23 ± 0.01 890 ± 20 570 ± 40 1.6 ± 0.1 16.3 ± 0.3 59 ± 2 9.8
Hyalistil Bio 0.21 ± 0.01 1050 ± 10 500 ± 40 2.1 ± 0.1 17.5 ± 0.6 63 ± 1 11.6
Octilia Natural 0.10 ± 0.01 1170 ± 10 610 ± 60 1.9 ± 0.2 18.5 ± 0.4 67 ± 2 3.7
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Table 2
Results of SEC-TDA analyses of the HA samples used for the optimization study:
values of weight average molar mass (Mw), numeric average molar mass (Mn), poly-
dispersity index (Mw/Mn), intrinsic viscosity ([]), hydrodynamic radius (Rh) are
reported.
Sample SEC-TDA analysis
Mw (kDa) Mn(kDa) Mw/Mn [] (dL/g) Rh(nm)
HA1100 1120 ± 100 730 ± 70 1.5 ± 0.1 18.7 ± 1.8 67 ± 7
HA800 800 ± 10 490 ± 9 1.6 ± 0.0 14.5 ± 0.3 54 ± 1
radius coherently varied with molecular weight and were con-ion of the MHS  curves derived from the SEC-TDA analyses; (b) ﬂow curves (dynamic
iscosity as a function of the shear rate) registered at 35 ◦C.
o ∼1200 kDa. Most of the products (Bluyal, Blugel, Hyabak, Artelac
plash) had equivalent distribution widths (Mw/Mn 1.6), and Hyal-
stil Bio and Octilia Natural showed higher polydispersity (Mw/Mn of
.9 and 2.1, respectively). Intrinsic viscosity ([]) values coherently
ecreased with the decrease in chain length. The same trend was
ound for the hydrodynamic radius. The values of HA concentration
ere consistent with the ones indicated in the packaging inserts.
onformational information could also be derived from the SEC-
DA analyses. Actually, as it is shown in Fig. 1a, the MHS  curves
log [] vs log Mw) of the commercial samples evidently over-
ap. This means that chains from the diverse samples having the
ame molecular weight, also exhibit the same intrinsic viscosity,
nd therefore, the same hydrodynamic volume, the same arrange-
ent (conformation) in solution (Harding, Rowe, & Horton, 1992;
okputsa, Jumel, Alexander, & Harding, 2003; La Gatta et al., 2011;
a Gatta et al., 2010). Finally, hydrodynamic analyses corroborated
he limited data reported about the ranges of polymer molecularHA500 470 ± 20 240 ± 10 1.9 ± 0.1 9.8 ± 0.2 40 ± 1
HA250 250 ± 3 160 ± 6 1.6 ± 0.1 6.7 ± 0.1 29 ± 1
weights and concentrations generally encountered in the products
on the market (Guillaumie et al., 2010; Johnson et al., 2006; Liu
et al., 2014; McDonald et al., 2002).
The ﬂow curves of the preparations (dynamic viscosity as a
function of the shear rate) are reported in Fig. 1b and the zero-
shear viscosity values, derived from these curves, are indicated in
Table 1 (last column). The samples greatly differed in viscosity: 0
in the range 3.7–24.2 mPa  s. A crucial ﬁnding emerged. As expected,
commercial combinations of molecular weights/concentrations
resulted in proper viscosities that were within the limit reported
for the speciﬁc use; however, the 0 values of most formulations
(Table 1) were much lower than the limit. This indicates these are
not optimized products since the drainage can be improved. Blugel
had the most optimized drainage based on its zero-shear viscosity
(24.2 mPas); therefore, this clinically accepted viscosity was chosen
as the target value for the following optimization studies.
The rheological characterization highlighted that commercial
preparations also differ for viscosity dependence on shear rate
(Fig. 1b). Most of the products exhibited a viscosity almost con-
stant with the shear rate predicting a same contrast to drainage at
rest (low shear rates) and during blinking (high shear rates); while,
a pseudoplastic behaviour was observed for the most viscous sam-
ple (Blugel) indicating a resistance to removal diminishing under
blinking conditions.
3.2. Hydrodynamic characterization of the HA samples used in
this work
The results of the hydrodynamic characterization of the HA sam-
ples used for the optimization study are reported in Table 2. The
four samples signiﬁcantly differed in molecular weight with Mw
values equal to 1120 ± 100, 800 ± 10, 470 ± 20, and 250 ± 3 kDa for
HA1100, HA800, HA500, and HA250, respectively. The HA1100,
HA800, and HA250 samples had the narrowest distributions
(Mw/Mn 1.5 and 1.6) while the polydispersity was  slightly higher
(Mw/Mn 1.9) for HA500. The intrinsic viscosity and hydrodynamicsistent with literature data (La Gatta et al., 2013; La Gatta, Papa,
Schiraldi, & De Rosa, 2016). The MHS  curves of the linear HA sam-
ples overlap with the ones of commercial formulations (data not
R. Salzillo et al. / Carbohydrate Pol
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videnced; (b) relationship between Mw and concentration for formulations exhibit-
ng ideal 0 (24.2 mPa  s); (c) ﬂow curves for selected formulations and Blugel.
hown) indicating, as discussed above, equivalent conformation
nd, therefore, the presence of linear, naturally occurring HA in
ommercial products (Harding et al., 1992; Hokputsa et al., 2003;
a Gatta et al., 2010; La Gatta et al., 2011). Overall, results in Table 2
ndicate that the HA samples used cover the range of molecular
eights found on the market. In addition, a comparison of the data
n Table 2 and in Table 1 indicates similarities between HA1100 and
luyal,  Blugel,  and Octilia Natural.
.3. Viscosity measurements
Flow curves were determined for HA1100, HA800, HA500, and
A250 at several concentrations (data not shown). The depen-
ence of the zero shear viscosity (0) on the biopolymer amount
n solution was derived for each HA sample (Fig. 2a). As shown,
egardless of chain length, viscosity exponentially increased with
oncentration; however, this dependence became more marked
ith the increase in molecular weight. This is consistent with the
ighly viscosifying properties of HA being mainly due to physical
ntanglements between polymer chains that are favoured by the
resence of long chains and/or high concentrations.ymers 153 (2016) 275–283 279
The curves in Fig. 2a were used to derive, for each molecular
weight, the biopolymer amount needed to have a 0 value equal to
Blugel, which was  the most viscous among the commercial prod-
ucts analyzed. The amounts were: HA1100-0.28%, HA800-0.40%,
HA500-0.67%, and HA250-1.03%. When HA1100 is dissolved, the
desired viscosity is reached at a low HA content (0.28 wt%), simi-
lar to the commercial products. When molecular weight decreases,
higher polymer amounts, up to about 3.3-fold more than found in
Blugel,  have to be considered to maintain optimal viscosity.
The relationship found between Mw (in the range
250–1100 kDa) and the concentration of the preparations exhibit-
ing zero-shear viscosity equal to 24.2 mPa  s is reported in Fig. 2b.
This relationship is expected to be valuable for designing topical
ophthalmic preparations containing HA. Actually, all the formula-
tions identiﬁed by the curve in Fig. 2b can be considered “optimum”
since they exhibit a viscosity very close to the maximum value for
the intended application and already exploited clinically. Among
the optimal formulations, HA1100-0.28%, HA800-0.40%, HA500-
0.67%, and HA250-1.03%, which cover the whole range of molecular
weights considered, were selected for further characterization.
The ﬂow curves of the selected preparations and of the best
performing on the market (Blugel) are reported in Fig. 2c to better
compare viscosity dependence on the shear rate. As expected, the
HA1100 formulation and Blugel behave similarly; therefore, they
were considered equivalent. When considering the other formula-
tions, it is evident that, although having the same (maximized) 0,
they behave differently when the shear rate increases. In particu-
lar, the reduction in viscosity lessens with the decrease of molecular
weight with HA250, which maintains a constant viscosity under the
conditions applied. Consequently, when at high shear rate values,
the molecular weight was  inversely proportional to the viscosity of
the formulation. Such differences in the capacity to maintain viscos-
ity at high shear rate values, more closely simulating in vivo blinking
conditions, are signiﬁcant during application. The lower the molec-
ular weight (the higher the concentration), the more likely the
formulation will be retained in vivo during blinking. Addition-
ally, when considering the similarities between HA1100-0.28% and
Blugel, the curves in Fig. 2c suggest all the formulations containing
HA with molecular weights <1100 kDa should have bioavailability
values that are superior to the commercially available preparations.
It is worth underlying that no polymer degradation occurs at
the high shear rate values experienced in this study: for all the
samples analyzed, ﬂow curves were registered also from high to
low shear rate and they perfectly overlap with the ones obtained at
the increase of the shear rate in the same interval (data not shown).
3.4. Mucoadhesion measurements
Mucoadhesiveness studies were performed to fully evaluate the
potential for formulations to be retained on the ocular surface. Gas-
tric mucin was employed due to its similarities to ocular mucin,
which is not commercially available (Ceulemans & Ludwig, 2002).
The biopolymer concentration used simulated the concentration
in the corneo-conjunctival epithelium and the experimental con-
ditions were carefully designed to simulate, as close as possible, the
conformation of mucin in the eye (Ceulemans & Ludwig, 2002).
The results from mucoadhesion measurements are shown in
Fig. 3. The HA samples were compared at the same concentra-
tion in Fig. 3a. The mucoadhesion index (%) of the solutions,
calculated as described in the paragraph 2.4.2, is reported as a
function of the shear rate. When considering low shear rate val-
ues, HA1100 shows the highest mucoadhesion index, followed by
HA800, HA500, and HA250. For all solutions, mucoadhesiveness
decreases with the shear rate; however, the higher the molecular
weight, the more marked the trend is. Thus, HA1100 is the most
mucoadhesive until the shear rate reaches about 60 s−1; then, the
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Mucoadhesion was evaluated for each molecular weight, at
arying concentrations, and the dependence of %, calculated at
he 33.9 s−1 shear rate, on concentration is reported in Fig. 3b.
he strength of the formulation/mucin interaction exponentially
ncreases with HA concentration; the higher the molecular weight,
he more notable the boost in mucoadhesiveness is with the
ncrease in polymer amount.
Overall, the results shown in Fig. 3a and b indicate that the
ncrease of both molecular weight and concentration positively
ffects the capacity of formulations to interact with mucin. How-
ver, for each molecular weight in the range considered, the
aximum achievable mucoadhesiveness is that of the formula-ymers 153 (2016) 275–283
tions identiﬁed by the curves in Fig. 2b, with higher concentrations
resulting in excessive viscosity. Therefore, the formulations iden-
tiﬁed as optimal in terms of viscosity were also the most
advantageous for mucoadhesive properties.
In Fig. 3c the mucoadhesion proﬁles of the selected formu-
lations are reported. In the region of low shear rate values, the
rank in mucoadhesiveness is HA500-0.67% > HA800-0.4% > HA250-
1.03% > HA1100-0.28%. The increase in shear rate affected the
mucoadhesiveness of preparations differently. As a result, in the
region of high shear rate values, mucoadhesion was  inversely
related to biopolymer molecular weight (increases with HA concen-
tration): the shorter the chains (the higher the HA concentration),
the stronger the interaction with mucin. Considering mucoad-
hesiveness dependence on molecular weight and concentration
(Fig. 3a and b), the speciﬁc combinations HA molecular weight-
amount within the preparations are rationally responsible for the
relative mucoadhesiveness at rest conditions. The different effect of
shear rate on mucoadhesiveness depending on polymer molecular
weight (Fig. 3a) is reasonably at the basis of the predominant con-
centration effect registered at high shear conditions (the effect of
molecular weight becomes negligible). Consequently, as with vis-Fig. 4. Results of oscillatory measurements. (a) Dynamic moduli as a function of
strain at 0.1 s−1 frequency and (b) dynamic moduli as a function of frequency at
constant strain (0.045%) for HA500/mucin mixtures. Measurements were performed
at 35 ◦C. The trends shown are representative of all mixtures mucine/(selected HA
sample).
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Overall, based on the results of rheological measurements, the
elected formulations should exhibit a retention on the ocular sur-
ace that is signiﬁcantly improved over the commercially available
roducts. Enhanced performance should be expected by decreasing
olecular weight (increasing biopolymer concentration).
.5. Oscillatory measurements (investigation of polymer/mucin
nteractions)
The interaction of a mucoadhesive polymer with mucin may
ccur by any of the following mechanisms: molecular interpenetra-
ion (physical entanglements), van der Waals bonds, electrostatic
orces, hydrogen bonds, etc. (Ludwig, 2005). Oscillatory measure-
ents of the HA formulations/mucin mixtures were performed in
rder to provide information about the type of interaction. Results
re reported in Fig. 4. In particular, the results of the strain sweep
est and of the frequency sweep test for the HA500-0.67%/mucin
ixture, which is representative of all samples, are reported in
ig. 4a and b, respectively. G′ ′ values were higher than G′ values in
he whole strain interval explored (Fig. 4a). This relative magnitude
f the moduli is indicative of physical entanglements between the
wo biopolymers (Ceulemans & Ludwig, 2002). Such a structure was
onﬁrmed by the results of the frequency sweep. The mechanical
ig. 5. Optical microscope images of PCECs after desiccation in no protective conditions 
nd  of cells not exposed to dehydration and to HA solutions (CTR).ymers 153 (2016) 275–283 281
spectrum in Fig. 4b indicates the presence of an entangled network
that behaves elastically with G′ exceeding G′ ′ at high frequencies
(low relaxation time); while, at low frequencies (high relaxation
times), chains can disentangle and a G′/G′ ′ crossover was registered
(Ceulemans & Ludwig, 2002; Cowman & Matsuoka, 2005). This type
of interaction is consistent with the trend found for mucoadhesive-
ness as a function of HA molecular weight and concentration (Fig. 3a
and b) and with the dependence of mucoadhesiveness on the shear
rate (Fig. 3a and c).
3.6. In vitro evaluation of corneal (epithelial cells) protection
against dehydration
Considering the massive use of HA-based eye drops for the treat-
ment of eye dryness disorders, the more concentrated formulations
(HA500-0.67%, and HA250-1.03%) were evaluated in vitro with
respect to HA1100-0.28%, representative of the best performing
product on the market, for their capacity to preserve the viability of
PCECs during desiccation trials. The formulas were also tested after
various dilutions (1:3, 1:10, and 1:30) to evaluate the HA dilution
in the tear ﬁlm that occurs in vivo immediately after instillation,
and during progressive drainage of the formulation from the ocular
surface.
(NC), after desiccation precedeed by treatment with HA formulations (not diluted)
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Results are reported in Figs. 5 and 6. Fig. 5 shows optical micro-
cope images of PCECs exposed to desiccation under no protective
onditions (NC), or after being treated with the HA formulations
not diluted) and of cells that were not exposed to dehydration
CTR). It is evident that NC cells exhibited a “stressed” (non-typical)
orphology and cell mortality with respect to CTR cells. In the sam-
les pre-treated with HA prior to desiccation, typical morphology
nd a higher rate of survival can be observed regardless of the spe-
iﬁc formula used. The same qualitative result was obtained when
ormulations were tested after a 1:3 dilution (data not shown).
hen the HA concentration was lowered 10- and 30-fold, the typ-
cal morphology and high survival rate could be still observed in
ells pre-treated with HA500 and HA250; while, changes in mor-
hology and mortality increased with the dilution in cells treated
ith HA1100 (data not shown).
The microscopic observation was conﬁrmed by the results of
uantitative analysis (Fig. 6). The applied stress was responsible for
0% cell mortality in the NC (no protective conditions) with respect
o the CTR (not stressed cells). Under the same stress, 80–100%
urvival rates were estimated for cells pre-treated with selected
ormulations at 1:1 and 1:3 dilutions, conﬁrming the same almost
otal protective effect displayed by all the HA forms evaluated. At a
:10 dilution, there was about 90% cell viability with respect to the
TR measured for HA500 and HA250 samples; while, a lower (about
0% cell viability), but still evident protective effect, was registered
or HA1100. When highly diluted (1:30), HA500 and HA250 were
till able to protect PCECs from desiccation (about 70–75% survival
ate), while no signiﬁcant effect was found for HA1100.
These results are in line with the hypothesis that the protective
ffect displayed by HA-based preparations on corneal epithelium
s related to the polymer water retaining capacity (Hill-Bator et al.,
014; Nakamura et al., 1993). The ﬁndings are important in view
f application: with equal drainage (dilution) rates, higher HA
mounts in the formulation correspond with longer-lasting efﬁ-
acy in vivo. Since more concentrated formulations are expected to
e retained longer in situ, the efﬁcacy should be further improved.
. ConclusionsIn conclusion, we developed HA-based eye drop formulations
hat we expected will maximally reduce the drainage rate, while
voiding an excessive increase in viscosity. Comparisons with com-
ercial products predicted there will be enhanced bioavailability
ig. 6. Results of quantitative determination of the protective effect against dehydration
onditions or after treatment with HA preparations, differently diluted.
Indicates the formulations exhibiting a signiﬁcant protective effect with respect to NC (p
*Indicates, signiﬁcant differences among the formulations tested, the red bar, at 10 and 3ymers 153 (2016) 275–283
with the more concentrated formulation, which has the potential
to exhibit the longest retention time in the tear ﬁlm. This ﬁnding
is valuable in the tuning of formulations, including HA, to extend
the precorneal residence time of the active ingredient. The prepa-
rations also surpassed the commercially available products in their
ability to protect the corneal epithelium from dehydration. This
outcome, combined with the enhanced bioavailability, suggests
the developed formulations may  be promising medications for the
treatment of dry eye disorders. Finally, this research provided more
insight into the importance of the combined effect of polymer size
and concentration on the rheological and mucoadhesive properties
of topical ophthalmic preparations incorporating a bioavailability-
enhancer; thus, it was  a useful reference study for the optimization
of similar products.
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